On June 15, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, reported that the Company presentation at BIO International Convention is now available at View Source (Press release, Oncotelic, JUN 15, 2022, View Source [SID1234616007]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The JVCo IPO- is on track for 2023 with anticipated minimum valuation of 200M / Range 1-5B
OT-101 is being combined with most known immunotherapies including MPM/Keytruda/ Merck, NSCLC/Tecentriq/Genentech, and others are in various stages of initiation
OT-10 treatment of high- risk COVID patients reduced mortality from 100% to 50%, p=0.003.